Quotient Bioresearch has released a white paper as part of its Evidence information series, which is available for download.
Biomarkers in Respiratory Disease, Part 1: Chronic Obstructive Pulmonary Disease (COPD) will explore the value that biomarkers can add to drug discovery and development in therapeutic areas.
The programme includes print and e-newsletters that regularly review the company's scientific publications, as well as presentations on Quotient Bioresearch expertise and an integrated clinical service offering - Synthesis-to-Clinic.
The white paper discusses how the combination of biomarkers from three sub-pathologies (oxidative stress, inflammation and tissue remodelling) with physiological assessment of lung function may provide an early indication of disease modification.
